IHCU:LSE:LSE-iShares S&P 500 Health Care Sector UCITS ETF USD (Acc) GBP (GBX)

ETF | Others |

Last Closing

USD 910

Change

-1.00 (-0.11)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

+2.25 (+1.22%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+2.13 (+1.83%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.06 (-0.41%)

USD 572.76B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.09 (-0.47%)

USD 572.76B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-1.45 (-2.01%)

USD 266.08B
0QZO:LSE 0QZO

+0.45 (+0.48%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

-0.15 (-0.48%)

USD 208.06B
0QZ3:LSE Qualcomm Inc.

+0.57 (+0.34%)

USD 202.26B
0R24:LSE Intel Corp.

+0.26 (+1.15%)

USD 196.14B

ETFs Containing IHCU:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.08% 56% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.08% 54% F 58% F
Trailing 12 Months  
Capital Gain 11.72% 37% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.72% 35% F 44% F
Trailing 5 Years  
Capital Gain 70.97% 79% B- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.97% 77% C+ 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 11.29% N/A N/A 72% C
Dividend Return 11.29% N/A N/A 71% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.66% N/A N/A 84% B
Risk Adjusted Return 130.36% N/A N/A 99% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike